Symbols

IPSC

Century Therapeutics·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 2

Bearish signal 3

Ample Liquidity

High Gross Profit Margin

Significant Revenue Decline

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About IPSC

Century Therapeutics, Inc.

An innovative biotech company that develops induced pluripotent stem cell -derived cell therapies in immuno-oncology

Industry

Biological Technology

Established Date

03/05/2018

Listing Date

06/18/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

140

Fiscal Year Ends

12-31

Website

www.centurytx.com

Security Type

Common stock

Office address

25 N 38th Street, 11th Floor, Philadelphia, Pennsylvania 19104

Business

Introduction

Century Therapeutics, Inc., was incorporated in Delaware on March 5, 2018. The Company is an innovative biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of solid tumors and hematological malignancies with significant unmet medical needs. The company has created a comprehensive allogeneic cell therapy platform that includes industry-leading induced pluripotent stem cells, or iPSCs, differentiation technology to generate immune effector cells from iPSCs or iPSC-derived cells, clustered regularly spaced short palindrome repeats, or CRISPR, mediated precision gene editing that enables the integration of multiple transgenes and removal of target genes designed to optimize cell product performance, advanced protein engineering capabilities, To develop proprietary next-generation chimeric antigen receptor or CAR cell products that are influenced by the host immune system and have state-of-the-art manufacturing capabilities designed to minimize product development and supply risks.

Company Financials

EPS

IPSC has released its 2025 Q3 earnings. EPS was reported at -0.4, versus the expected -0.38, missing expectations. The chart below visualizes how IPSC has performed over recent quarters, highlighting trends in earnings surprises.